First-Line HIV/AIDS Treatments: Research
 SPARTAN: Two-Drug, NRTI-Sparing Strategies Continue to Disappoint (June 8, 2012)
From Journal Watch
On TheBodyPRO.com
- What Lies Ahead: Trends in HIV Treatment and Care (March/April 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- HIV/AIDS Researcher David Ho Wins NIDA's 2011 Avant-Garde Award (August 12, 2011)
Ho plans to develop a revolutionary, long-acting HIV therapy to improve adherence to treatment.
From U.S. National Institutes of Health
On TheBodyPRO.com
- New Experimental Drug Blocks HIV Infection Early, Scientists Report (December 23, 2010)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
On TheBodyPRO.com
- Small Study Suggests Once-Daily MVC Plus ATV/r as Viable First Regimen (July 26, 2010)
From National AIDS Treatment Advocacy Project
- Kaletra/Isentress Shows Promise as HIV Nuceleoside-Sparing Regimen for First-Line Treatment (July 20, 2010)
From AIDSmeds.com
- First-Line Lopinavir/r/Raltegravir (With No NRTIs) in Treatment Naive (July 19, 2010)
From National AIDS Treatment Advocacy Project
- Side Effect and CD4 Differences in Four ACTG 5202 Arms at 96 Weeks (February 18, 2010)
From National AIDS Treatment Advocacy Project
- Overweight People With HIV See Lower CD4 Gain While on HIV Medications, Study Suggests (November 19, 2009)
An interview with Nancy Crum-Cianflone, M.D., M.P.H.
In HIV News & Views, from TheBody.com
- HIV Treatment Lagging Behind for Many Infected Youth (May 3, 2009)
Health care providers often decide not to start young HIVers on HIV treatment even though their CD4 count is below 350, a new U.S. study has found.
From Johns Hopkins University
On TheBodyPRO.com
VIEW ALL ARTICLES
|
Advertisement
|
Email
Glossary
